Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1274571

registered interest
date	07/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the availability of glass vials for COVID-19 vaccine distribution.
tabling member printed	Lord Campbell-Savours
uin	HL11866
answer	answer is ministerial correction date of answer 21/01/2021 answer text <p>The UK has a sufficient number of glass vials available, due to orders already placed.</p> answering member printed Lord Callanan question first answered 21/01/2021 17:28:26 answering member 4336 label Biography information for Lord Callanan
tabling member	499 label Biography information for Lord Campbell-Savours

1274572

registered interest
date	07/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of (1) the quantity of glass vials that will be needed to distribute COVID-19 vaccines, (2) the capacity to manufacture these vials, and (3) any procurement or delivery issues that may arise.
tabling member printed	Lord Campbell-Savours
uin	HL11867
answer	answer is ministerial correction date of answer 06/04/2021 answer text <p>The procurement of vials is the responsibility of the manufacturer and the United Kingdom Government has actively engaged with each manufacturer regarding manufacturing capacity, procurement and delivery to ensure enough stock is available, providing additional support where required. The UK has a sufficient number of glass vials available, due to orders already placed with manufacturers.</p> answering member printed Lord Bethell question first answered 06/04/2021 13:03:27 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274573

registered interest
date	07/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the requirements of the contract they awarded to Wockhardt Ltd, to help in the production of COVID-19 vaccines, are currently being fulfilled.
tabling member printed	Lord Campbell-Savours
uin	HL11868
answer	answer is ministerial correction date of answer 14/04/2021 answer text <p>The Oxford/AstraZeneca vaccine is currently being filled and finished at the Wockhardt site.</p><p>The Government has recently extended Wockhardt’s contract from 18 to 24 months to ensure that we have uninterrupted capability into 2022. Specific details of contract fulfillment are commercially sensitive.</p> answering member printed Lord Bethell question first answered 14/04/2021 11:07:08 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274574

registered interest
date	07/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they have entered into any contracts with (1) Oxford Biomedica, (2) Cobra, and (3) Halix, in relation to the production of COVID-19 vaccines; and, if so, what plans they have to make the terms of these contracts available to the public.
tabling member printed	Lord Campbell-Savours
uin	HL11869
answer	answer is ministerial correction date of answer 21/01/2021 answer text <p>The Government has not entered into a contract with any of the named companies.</p> answering member printed Lord Callanan question first answered 21/01/2021 17:16:47 answering member 4336 label Biography information for Lord Callanan
tabling member	499 label Biography information for Lord Campbell-Savours

1274487

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what administrative arrangements are in place to ensure that people comply with the requirement to receive a second dose of a COVID-19 vaccine; and what information is being retained as to the identity of those who do not receive a second dose of a vaccine having been scheduled to do so.
tabling member printed	Lord Campbell-Savours
uin	HL11801
answer	answer is ministerial correction date of answer 22/01/2021 answer text <p>The United Kingdom operates a system of informed consent for vaccinations. When advice from the Joint Committee on Vaccination and Immunisation informed changes to the timings of the secondary dose, general practitioners (GPs) were asked to rebook the appointments. Vaccination centres book in appointments with individuals for both the first and second dose at the same time. Additionally, vaccinations are noted in GP health records and the National Immunisation Management System, which can be accessed by the national booking service to follow up on any missed second doses.</p><p> </p><p>Previous incomplete vaccinations, where the course has been interrupted or delayed, should be resumed using the same vaccination. However, the first dose should not be repeated.</p> answering member printed Lord Bethell question first answered 22/01/2021 10:38:33 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274488

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many people in total were vaccinated against COVID-19 in the UK using (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine in each week since the beginning of 1 December 2020.
tabling member printed	Lord Campbell-Savours
uin	HL11802
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The information is not collected in the format requested.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:19:42 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274489

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what estimate they have made of the duration of protection from COVID-19 provided by (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine; and what estimate they have made of the length of time a person who receives (a) only a first dose, and (b) two doses, of (i) the Oxford/AstraZeneca and (ii) the Pfizer/BoNTech, vaccine is protected from COVID-19.
tabling member printed	Lord Campbell-Savours
uin	HL11803
answer	answer is ministerial correction date of answer 14/04/2021 answer text <p>The total length of protection from vaccines against COVID-19 is not yet fully understood. Vaccine developers and manufacturers continue to collect data on the performance of their vaccines. Through their surveillance strategy Public Health England (PHE) continues to assess the effectiveness of vaccines, including duration of protection. A copy of PHE’s <em>COVID-19 vaccine surveillance Strategy </em>is attached<em>.</em></p><p>On 26 January the Joint Committee on Vaccine and Immunisation (JCVI) published an online report, <em>Optimising the COVID-19 vaccination programme for maximum short-term impact</em>. The report found that short-term vaccine efficacy from the first dose of the Pfizer/BioNTech vaccine is calculated at around 90% and from the first dose of the Oxford/ AstraZeneca vaccine is calculated at around 70%, with high protection against severe disease.</p><p>Given the high level of protection afforded by the first dose, models suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses. The second dose is important to provide longer lasting protection and is expected to be as or more effective when delivered at an interval of 12 weeks from the first dose. The JCVI has based their advice on the assumption that protection from a first dose of either vaccination will wane in the medium term and that a second dose will offer more long term protection.</p> answering member printed Lord Bethell question first answered 14/04/2021 16:06:57 answering member 4708 label Biography information for Lord Bethell attachment 1 file name COVID-19_vaccine_surveillance_strategy_March21 (1).pdf title COVID-19 Vaccine Surveillance Strategy
tabling member	499 label Biography information for Lord Campbell-Savours

1274490

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many, and what percentage of the total of, (1) care home residents, (2) care home staff, (3) frontline health workers, and (4) patients over 80, have been vaccinated against COVID-19 in (a) England, (b) Scotland, (c) Wales, and (d) Northern Ireland.
tabling member printed	Lord Campbell-Savours
uin	HL11804
answer	answer is ministerial correction date of answer 27/04/2021 answer text <p>NHS England releases weekly vaccination data which shows that as of 15 April:</p><p>- 94.2% eligible residents in older adult care homes in England have received at least their first dose of a COVID-19 vaccine;</p><p>- 79.4% eligible staff in older adult resident care homes have received at least their first dose; and</p><p>- 95.2% of patients over 80 years old have received at least their first dose of a COVID-19 vaccine.</p><p>The percentage of National Health Service trust health care workers who have received at least their first dose is not currently available, as NHS England’s data does not currently include all frontline health workers as a sub-group.</p><p>COVID-19 vaccination data for Scotland, Wales and Northern Ireland is not collected centrally in the format requested as this is a devolved matter.</p> answering member printed Lord Bethell question first answered 27/04/2021 12:15:39 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274491

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is the optimum gap between the first and second dose of (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, COVID-19 vaccine for securing the longest period of protection against COVID-19.
tabling member printed	Lord Campbell-Savours
uin	HL11805
answer	answer is ministerial correction date of answer 08/04/2021 answer text <p>The Medicines and Healthcare products Regulatory Agency’s (MHRA’s) Information for Healthcare Professionals regarding the Pfizer vaccine states that a second dose of it should be given at least 21 days after the first dose. For the AstraZeneca vaccine, the Information for Healthcare Professionals states that the second dose should be given between four and 12 weeks after the first dose. This advice is based on clinical trial data and other information submitted to MHRA by the manufacturer.</p><p>Based on trial data showing the effectiveness of both vaccines, the Joint Committee on Vaccination and Immunisation (JCVI) advised that both vaccines should be given up to 12 weeks apart. The JCVI also advised that priority should be given to having a greater number of people given a first dose, which would have a greater public health impact than prioritising second doses.</p> answering member printed Lord Bethell question first answered 08/04/2021 10:55:03 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours

1274492

registered interest
date	06/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assurances AstraZeneca gave about its commitment to manufacture the Oxford vaccine prior to either (1) a successful testing programme, or (2) approval by the Medicines and Healthcare products Regulatory Agency.
tabling member printed	Lord Campbell-Savours
uin	HL11806
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>Assurances agreed between the Government and Oxford/AstraZeneca are bound by commercially confidential contracts.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:33:46 answering member 4708 label Biography information for Lord Bethell
tabling member	499 label Biography information for Lord Campbell-Savours